Snake Meat......source of chinese virus
- Thread starter MacTheKnife
- Start date
- Status
A large response to the vaccine's website occurred:
iz.ru
' He said that on the first day of the official website of the vaccine, users from 188 countries became visitors to the resource.'
Глава РФПИ назвал требуемый срок для вакцинации всех россиян от COVID-19
Вакцинация всего населения России от коронавирусной инфекции может быть проведена в срок от 9 до 12 месяцев. Об этом в среду, 12 августа, заявил глава Российского фонда прямых инвестиций (РФПИ) Кирилл Дмитриев.
iz.ru
However, Gamaleya has not released data on its early phase:
12 Aug 2020 Moscow Times
www.themoscowtimes.com
12 Aug 2020 Moscow Times
Russia’s Covid-19 Vaccine Breaches Crucial Scientific and Ethical International Standards - The Moscow Times
Opinion | Russian President Vladimir Putin has announced regulatory approval of a Covid-19 vaccine developed by Moscow's Gamaleya Institute.
www.themoscowtimes.com
Now closed for review, the thread 'Doctors Are Coming Out in Droves Saying Hydroxychloroquine Works' has a report by TAZ @ #1,962:
Why Lopinavir and Hydroxychloroquine Do Not Work on Covid-19
The first contradiction we find is that the report reifies the lungs of the patient for its argument against hydroxychloroquine (hereafter, hcq), whilst reifying lopinavir in the lungs. In reality, hcq is working elsewhere in the body as well. It depends on the dissemination of the virus. First, we'll confirm that the URL is working so the reader can refer back to it if required.
Why Lopinavir and Hydroxychloroquine Do Not Work on Covid-19
Why lopinavir and hydroxychloroquine do not work on COVID-19
Lopinavir is a drug against HIV, hydroxychloroquine is used to treat malaria and rheumatism. Until recently, both drugs were regarded as potential agents in the fight against the coronavirus SARS-CoV-2. Researchers have now discovered that the concentration of the two drugs in the lungs of...
sciencedaily.com
The first contradiction we find is that the report reifies the lungs of the patient for its argument against hydroxychloroquine (hereafter, hcq), whilst reifying lopinavir in the lungs. In reality, hcq is working elsewhere in the body as well. It depends on the dissemination of the virus. First, we'll confirm that the URL is working so the reader can refer back to it if required.
The lopinavir report states: 'when the inflammation was blocked with the interleukin-6 inhibitor, tocilizumab, lopinavir plasma levels were significantly lower than the ones in patients without tocilizumab treatment.'
On 12 Jul 2020, we mentioned tocilizumab in conjunction with a dengue trajectory (post #740):
www.ncbi.nlm.nih.gov
'....Sixty-six patients received tocilizumab....most patients received concomitant glucocorticoids and hydroxychloroquine....This study found limited clinical improvement in patients that received tocilizumab in the setting of severe COVID-19.'
But this is supposedly the precise type of patient in which hcq shows improvement.
On 12 Jul 2020, we mentioned tocilizumab in conjunction with a dengue trajectory (post #740):
Tocilizumab in patients with severe COVID-19: A single-center observational analysis - PubMed
Patients with coronavirus disease 2019 (COVID-19) may develop severe respiratory distress, thought to be mediated by cytokine release. Elevated proinflammatory markers have been associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, may be beneficial for severe...
www.ncbi.nlm.nih.gov
But this is supposedly the precise type of patient in which hcq shows improvement.
The lopinavir report continues:
'....Lopinavir levels were more than two- to three-fold higher than typically observed in HIV patients. Hydroxychloroquine levels were within normal range....Results strongly suggest that it is unlikely that both drugs reach sufficient concentrations to inhibit virus replication in the lung....WHO accepted the recommendation from the Solidarity Trial's International Steering Committee to discontinue the trial's hydroxychloroquine and lopinavir arms on 4 Jul 2020.
Professor Manuel Battegay -- co-leader of this study and head of the Division of Infectious Diseases and Hospital Epidemiology at the University Hospital in Basel -- mentioned that the results provide important pharmacological and antiviral insights to the rationale of discontinuing the lopinavir/ritonavir arm. In fact, they add scientific reasoning why hydroxychloroquine and lopinavir are not effective against SARS-CoV-2.
....
These results clearly indicate that drug metabolism enzymes (cytochrome P450 3A) are inhibited by systemic inflammation. "Caution is advised when prescribing CYP3A4 substrates such as lopinavir/ritonavir, or any other drug with a narrow therapeutic index to COVID-19 patients because of the risk of elevated drug levels and related toxicities," the authors state.'
'....Lopinavir levels were more than two- to three-fold higher than typically observed in HIV patients. Hydroxychloroquine levels were within normal range....Results strongly suggest that it is unlikely that both drugs reach sufficient concentrations to inhibit virus replication in the lung....WHO accepted the recommendation from the Solidarity Trial's International Steering Committee to discontinue the trial's hydroxychloroquine and lopinavir arms on 4 Jul 2020.
Professor Manuel Battegay -- co-leader of this study and head of the Division of Infectious Diseases and Hospital Epidemiology at the University Hospital in Basel -- mentioned that the results provide important pharmacological and antiviral insights to the rationale of discontinuing the lopinavir/ritonavir arm. In fact, they add scientific reasoning why hydroxychloroquine and lopinavir are not effective against SARS-CoV-2.
....
These results clearly indicate that drug metabolism enzymes (cytochrome P450 3A) are inhibited by systemic inflammation. "Caution is advised when prescribing CYP3A4 substrates such as lopinavir/ritonavir, or any other drug with a narrow therapeutic index to COVID-19 patients because of the risk of elevated drug levels and related toxicities," the authors state.'
A Heidelberg trial for hydroxychloroquine and CYP3A4 is apparently not yet published:
Hydroxychloroquine and Pantoprazole
dzif.clinicalsite.org/en/cat/2097/trial/4195
dzif.clinicalsite.org
Hydroxychloroquine and Pantoprazole
dzif.clinicalsite.org/en/cat/2097/trial/4195
Clinical Trials | German Center for Infection Research
About 500 scientists and physicians from 35 institutions nationwide jointly develop new vaccines, diagnostics and drugs in the fight against infections.
The same basic report from Basel (post #867) does not list in its references the Taiwanese report, below, although we will note reference #39 for further investigations of cutaneous phenomenon in suspected COVID-19 intermediate host, Neophcaena (previous post):
Basel
www.ncbi.nlm.nih.gov
'....ref. #39 Morita S, et al, Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients with Cutaneous or Systemic Lupus Erythematosis.'
Contra Zelenko, the Basel report did not use azithromycin or zinc with hydroxychloroquine.
Here one sees improved efficacy linking Raoult-Zelenko's tripartite protocol in previous messages:
Taiwan
www.ncbi.nlm.nih.gov
'....Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on days 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro.'
The Taiwanese report simply does not use zinc, a critical male factor.
Basel
Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations - PubMed
Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma...
www.ncbi.nlm.nih.gov
Contra Zelenko, the Basel report did not use azithromycin or zinc with hydroxychloroquine.
Here one sees improved efficacy linking Raoult-Zelenko's tripartite protocol in previous messages:
Taiwan
Treatment options for COVID-19: The reality and challenges - PubMed
An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of...
www.ncbi.nlm.nih.gov
The Taiwanese report simply does not use zinc, a critical male factor.
A rhabdomyolysis COVID case from Mexico shows a treatment regimen:
Jun 2020 Mexico City Rhabdomyolysis / COVID-19
www.ncbi.nlm.nih.gov
'....We started aggressive fluid and bicarbonate therapy as well as enoxaparin, azithromycin and ceftriaxone. The patient agreed to the use of compassionate drug therapy, so we started him on hydroxychloroquine and lopinavir/ritonavir. HIs condition deteriorated on the third day of hospitalization and he required invasive mechanical ventilation. Over the next two days, his condition continued to deteriorate, with fever, hypotension and high ventilatory requirements. His CRP (c-reactive protein) and IL-6 levels also increased (to 26.9 mg/dL and 275 pg/mL, respectively). His family agreed to the use of tocilizumab on a compassionate use scheme. Consequently, we gave him two doses of tocilizumab 400 mg intravenous on the fifth and sixth day after admission....On the seventh day after admission, his condition started to improve and he showed a decrease in lactic dehydrogenase, ferritin, CRP and PCT levels. It was possible to extubate him on the 12th day after admission. His clinical condition continued to improve and after a negative SARS-CoV2 test, we were able to finally discharge him on the 16th day after admission.'
Jun 2020 Mexico City Rhabdomyolysis / COVID-19
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19 - PubMed
The presence of rhabdomyolysis secondary to multiple infections has been reported, predominantly viral, but also bacterial and fungal. It is well known that COVID-19 can present a wide variety of complications during the course of infection; however, the presence of rhabdomyolysis as an initial...
www.ncbi.nlm.nih.gov
13 Aug 2020 CDC Warns America
yahoo.com
CDC director warns America is in for the ‘worst fall…we’ve ever had’
CDC director Robert Redfield warned in a WebMD interview on Wednesday that America is bracing for “the worst fall, from a public health perspective, we’ve ever had.” Rather, fall and winter become influenza’s time to shine. Read more: Does sunshine kill coronavirus?
yahoo.com
Social distancing parameters seem to have changed and may affect the legitimacy of public protest assemblages:
14 Aug 2020 Airborne COVID-19
https:// independent.co.uk/news/world/americas/coronavirus-latest-airborne-aerosol-outbreaks-social-distancing-a9667706.html
'....Confirmation of aerosol transmission, at distances of 6.5 and 15 feet (2 and 4.8 metres), was made by University of Florida experts in virology and aerosol science, according to a research paper published on the reprint server medRxiv.'
14 Aug 2020 Airborne COVID-19
https:// independent.co.uk/news/world/americas/coronavirus-latest-airborne-aerosol-outbreaks-social-distancing-a9667706.html
'....Confirmation of aerosol transmission, at distances of 6.5 and 15 feet (2 and 4.8 metres), was made by University of Florida experts in virology and aerosol science, according to a research paper published on the reprint server medRxiv.'
The Original Tree
Diamond Member
The source of the Virus is Bill Gates and his Lefty Satan Worshiping Globalist Friends.
This links to the CDC's report of yesterday:
14 Aug 2020 Izvestia,
Sobianin zaiavil o roste sluchaev grippa i orvi v Moskve
Sobyanin Announced Growth of Cases of Influenza and SARS in Moscow
V Moskve zafiksirovan rost sluchaev zabolevaniia ORVI, grippa i nekoronavirusnoi pnevmoniei, ob etom v piatnitsu, 14 avgusta, zaiavil mer stolitsy Sergei Sobianin.
In Moscow, an increase of cases of ARVI, influenza and non-coronavirus pneumonia was record. It was announced on Friday, 14 Aug, by the mayor of the capital, Sergei Sobianin.
"My uzhe segodnia vidim rost ORVI, grippa i chastichno dazhe pnevmonii, ne koronavirusnykh, a ob'chykh pnevmonii.
Today we already see an increase in ARVI, influenza and partially even pneumonia, not coronavirus, but ordinary pneumonia.
Konechno, kogda eto vse razov'etsia v takuiu uzhe ser'eznuiu stadiiu, nalozhenie dvukh infektsionnykh protsessov nichego khoroshego ne dast," -- skazal Sobianin v efire telekanala "Rossii 1."
Of course, when all this develops into such a serious stage, the superposition of two infectious processes will not do anything good."
On dobavil, chtov slozhivsheisia situatsii neobkhodimo kak mozhno ran'she nachat' privivat-sia ot grippa.
He added that in this situation it is necessary to start getting vaccinated against influenza as soon as possible.
Na etoi nedele prezident Rossii Vladimir Putin poruchil pravitel'stvu obespechit' finansirovanie vaktsinatsii ot grippa do 60% nasheleniia strany.
This week, Russian President Vladimir Putin instructed the government to provide funding for flu vaccinations for up to 60% of the country's population.
Rukovoditel' laboratorii genomnoi inzhenerii MPhTI Pavel Volchkov v razgovore s "Izvestiiami" otmetil, chto Rossii mozhet ne stolknut'sia do kontsa goda s novym shtammom grippa.
Head of the Laboratory of Genomic Engineering MIPT Pavel Voltchkov in conversation with "Izvestia" said that Russia could not face up to the end of the year with a new strain of influenza.'
14 Aug 2020 Izvestia,
Sobianin zaiavil o roste sluchaev grippa i orvi v Moskve
Sobyanin Announced Growth of Cases of Influenza and SARS in Moscow
V Moskve zafiksirovan rost sluchaev zabolevaniia ORVI, grippa i nekoronavirusnoi pnevmoniei, ob etom v piatnitsu, 14 avgusta, zaiavil mer stolitsy Sergei Sobianin.
In Moscow, an increase of cases of ARVI, influenza and non-coronavirus pneumonia was record. It was announced on Friday, 14 Aug, by the mayor of the capital, Sergei Sobianin.
"My uzhe segodnia vidim rost ORVI, grippa i chastichno dazhe pnevmonii, ne koronavirusnykh, a ob'chykh pnevmonii.
Today we already see an increase in ARVI, influenza and partially even pneumonia, not coronavirus, but ordinary pneumonia.
Konechno, kogda eto vse razov'etsia v takuiu uzhe ser'eznuiu stadiiu, nalozhenie dvukh infektsionnykh protsessov nichego khoroshego ne dast," -- skazal Sobianin v efire telekanala "Rossii 1."
Of course, when all this develops into such a serious stage, the superposition of two infectious processes will not do anything good."
On dobavil, chtov slozhivsheisia situatsii neobkhodimo kak mozhno ran'she nachat' privivat-sia ot grippa.
He added that in this situation it is necessary to start getting vaccinated against influenza as soon as possible.
Na etoi nedele prezident Rossii Vladimir Putin poruchil pravitel'stvu obespechit' finansirovanie vaktsinatsii ot grippa do 60% nasheleniia strany.
This week, Russian President Vladimir Putin instructed the government to provide funding for flu vaccinations for up to 60% of the country's population.
Rukovoditel' laboratorii genomnoi inzhenerii MPhTI Pavel Volchkov v razgovore s "Izvestiiami" otmetil, chto Rossii mozhet ne stolknut'sia do kontsa goda s novym shtammom grippa.
Head of the Laboratory of Genomic Engineering MIPT Pavel Voltchkov in conversation with "Izvestia" said that Russia could not face up to the end of the year with a new strain of influenza.'
August reports at Pubmed for COVID-19 include one for losartan. The FDA recalled losartan in summer of 2018 due to nitrosamine contamination, though the source country is yet unknown to this writer. It was surprising to the FDA then to find these impurities in ARBs (ACE2 blockers), and COVID-19 precisely targets ACE2 receptors.
COVID-19 / Losartan
www.ncbi.nlm.nih.gov
COVID-19 / Losartan
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics - PubMed
At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are...
www.ncbi.nlm.nih.gov
- Status
Similar threads
New Topics
-
-
BREAKING: US and China agree to reduce tariffs for 90 days- Started by TemplarKormac
- Replies: 3
-
Zone1 Loss of Wager Money Possibly the Reason Why Someone Would Threaten to Stab to Death the Children of Houston Astros Pitcher L McCullers?- Started by NewsVine_Mariyam
- Replies: 0
-
-
